Dishman Carbogen Amcis’ arm enters into joint funding agreement with longstanding Japan based customer

29 Apr 2021 Evaluate

Dishman Carbogen Amcis’ wholly owned subsidiary namely CARBOGEN AMCIS AG., Switzerland has entered into joint funding agreement with a longstanding Japan based customer to build a site extension at the Bubendorf site in Switzerland. The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

228.55 10.40 (4.77%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.